Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
RESEARCH TOOLSreports
Holding APLS?
Track your performance easily
APLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$26.28 - $73.80
Previous Close$28
Volume206.10K
Average Volume (3M)2.03M
Market Cap
$3.45B
Enterprise Value$3.52B
Total Cash (Recent Filing)$360.10M
Total Debt (Recent Filing)$474.51M
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Nov 04, 2024EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.74
Shares Outstanding121,766,328
10 Day Avg. Volume2,129,978
30 Day Avg. Volume2,034,342
Standard Deviation0.21
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)10.71
Price to Sales (P/S)5.42
Price to Cash Flow (P/CF)-102.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.60
Enterprise Value/Gross Profit10.42
Enterprise Value/Ebitda-11.65
Forecast
1Y Price Target
$66.00Price Target Upside142.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Apellis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessApellis reported better-than-expected, positive results for subq pegcetacoplan in two rare, serious kidney diseases (C3G/IC-MPGN), achieving a 68% placebo-adjusted reduction in proteinuria, exceeding expectations.
European Market OpportunitiesProcedural changes have been made regarding the European Medicines Agency's review process, renewing optimism for a positive opinion on approval for pegcetacoplan in Europe.
Financial PerformanceThe company reiterated they continue to expect to become cash flow positive without the need to raise any additional capital.
Bears Say
Market CompetitionIzervay is winning more new start patients with ~55% of patients, impacting Syfovre's market share.
Product Efficacy ConcernsThere have yet to be data convincingly demonstrating Syfovre use leading to clear, clinically meaningful functional benefit.
Regulatory ChallengesAPLS announced a final negative opinion from the European Medicines Agency on potential European regulatory approval for pegcetacoplan.
---
Ownership Overview
14.07% Insiders
31.49% Mutual Funds
0.18% Other Institutional Investors
33.01% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $26.28 and its highest was $73.80 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is Nov 04, 2024 which is in 13 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Aug 01, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.306 by $0.006.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -$0.28.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 121,766,330 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.306. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Apellis Pharmaceuticals Inc’s shares valued at 7M.
---
Apellis Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$66.00 (142.91% Upside)
$66.00 (142.91% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $28.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.6%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.06%
12-Months-Change
Fundamentals
Return on Equity
-109.19%
Trailing 12-Months
Asset Growth
-1.21%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
---
APLS Company Deck
---
APLS Earnings Call
Q2 2024
0:00 / 0:00
---
APLS Stock 12 Month Forecast
Average Price Target
$66.00
▲(142.91% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Best Analysts Covering APLS
1 Year
1 Year Success Rate
13/27 ratings generated profit
1 Year Average Return
+6.94%
reiterated a buy rating last month
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 48.15% of your transactions generating a profit, with an average return of +6.94% per trade.
---